| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/100-1/500 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Aurora kinase A, Aurora 2, Aurora/IPL1-related kinase 1, ARK-1, Aurora-related kinase 1, hARK1, Breast tumor-amplified kinase, Serine/threonine-protein kinase 15, Serine/threonine-protein kinase 6, Serine/threonine-protein kinase aurora-A, AURKA |
| Entrez GeneID | 6790 |
| WB Predicted band size | 45.8kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | This AIK antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 90-120 amino acids from the N-terminal region of human AIK. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于AIK(N-term)抗体的3篇参考文献示例：
1. **"Characterization of a Novel N-terminal Specific Antibody for Aurora Kinase AIK in Mitotic Regulation"**
*作者：T. Tanaka et al.*
摘要：该研究报道了一种针对Aurora激酶AIK N端结构域的单克隆抗体的开发，验证了其在HeLa细胞有丝分裂过程中定位及表达水平检测的特异性，证实AIK在纺锤体组装中的关键作用。
2. **"AIK (Aurora/Ipl1-related Kinase) N-terminal Antibody Application in Colorectal Cancer Prognosis"**
*作者：M. Lee & J. Park*
摘要：利用AIK N端抗体对结直肠癌组织进行免疫组化分析，发现AIK高表达与患者预后不良显著相关，提示其作为潜在生物标志物的价值。
3. **"Development and Validation of Polyclonal Antibodies Targeting the N-terminal Domain of Apoptosis-Inducing Kinase AIK"**
*作者：R. Chen et al.*
摘要：研究描述了AIK N端多克隆抗体的制备过程，通过Western blot和免疫荧光验证其特异性，并应用于探究AIK在TRAIL诱导的凋亡信号通路中的激活机制。
注：上述文献为模拟示例，实际引用时请核实真实来源及内容准确性。
The AIK (N-term) antibody is a specialized immunological tool designed to target the N-terminal region of the Aurora kinase A (AIK) protein, a critical serine/threonine kinase involved in cell cycle regulation. Aurora kinase A plays a pivotal role in mitotic progression, particularly in centrosome maturation, spindle assembly, and chromosomal segregation. Dysregulation of AIK is frequently associated with cancer, making it a key biomarker and therapeutic target in oncology research.
The AIK (N-term) antibody is typically generated using synthetic peptides or recombinant protein fragments corresponding to the N-terminal domain of Aurora kinase A. This region is often selected due to its unique antigenic epitopes, which enhance antibody specificity and reduce cross-reactivity with other Aurora kinase family members (e.g., Aurora B or C). Validated for applications like Western blotting, immunohistochemistry, and immunofluorescence, this antibody aids in detecting AIK expression levels, subcellular localization, and activation status in cell lines or tissue samples.
Its development has advanced studies on mitotic abnormalities, cancer mechanisms, and drug discovery. Researchers also utilize it to assess the efficacy of Aurora kinase inhibitors in preclinical models. Quality control often includes knockout validation to confirm target specificity, ensuring reliable data in both basic and translational research contexts.
×
